Kyowa Kirin

Kyowa Kirin

Kyowa Kirin was formed in 2008 through the merger of Kyowa Hakko Kogyo and Kirin Pharma, two entrenched names in Japanese fermentation and biotechnology. Kirin Holdings retains a 53.77% controlling stake, anchoring the firm within one of Japan's largest beverage-to-pharma conglomerates. Chairman and CEO Masashi Miyamoto has led the combined entity since inception, while President and COO Abdul Mullick is set to assume the CEO role in March 2026. The firm focuses its corporate venture and strategic partnership activity on its four core therapeutic areas: oncology, nephrology, immunology, and the central nervous system. Its investment posture is purely strategic — taking equity stakes and forming R&D collaborations with biotechnology companies whose assets align with its pipeline. A flagship partnership with Amgen Inc. is co-developing rocatinlimab (KHK4083), an anti-OX40 monoclonal antibody for atopic dermatitis. North American deal sourcing and alliance management run through hubs in Princeton, New Jersey, and a specialized research institute in La Jolla, California — placing the firm close to both the US capital markets and the San Diego biotech cluster. Operational infrastructure underscores the firm's hybrid pharma-investor model. Kyowa Kirin owns biologics manufacturing plants in Sanford, North Carolina, and across three Japanese prefectures, allowing it to scale production for portfolio companies it backs. In the EMEA region, a joint venture with Grünenthal manages the International Established Medicines portfolio — a cash-generative, non-core asset base that frees resources for pipeline investment. The firm also maintains a long-term partnership with the Health and Global Policy Institute (HGPI), signaling an interest in shaping market-access frameworks in Asia. What distinguishes Kyowa Kirin is its identity as a balance-sheet corporate venture investor embedded within a publicly listed operating company. Unlike standalone venture arms that raise third-party funds, Kyowa Kirin invests from its own P&L, aligning capital deployment directly with internal R&D priorities. The transition from Miyamoto to Mullick in 2026 marks the first major succession event since the 2008 merger, likely reinforcing the firm's commitment to global strategic investing from its Tokyo headquarters.